Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AMPE Stock Alerts

Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals logo
$0.0052 0.00 (0.00%)
As of 05/4/2026
Compare

AMPE vs. SCPS, VAXX, ARDS, TRVN, and NAVB

Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Ampio Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Ampio Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Ampio Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 7.65, indicating that its stock price is 665% more volatile than the S&P 500.

Summary

Ampio Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Vaxxinity?

Ampio Pharmaceuticals (NYSE:AMPE) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Vaxxinity Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Vaxxinity N/A N/A N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ampio Pharmaceuticals has a beta of 7.65, meaning that its stock price is 665% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -74.37, meaning that its stock price is 7,537% less volatile than the S&P 500.

Summary

Vaxxinity beats Ampio Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Aridis Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

Ampio Pharmaceuticals has a beta of 7.65, meaning that its stock price is 665% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, meaning that its stock price is 4,848% more volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Ampio Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Trevena?

Ampio Pharmaceuticals (NYSE:AMPE) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Trevena Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

Ampio Pharmaceuticals has higher earnings, but lower revenue than Trevena. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Ampio Pharmaceuticals has a beta of 7.65, suggesting that its stock price is 665% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Navidea Biopharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Ampio Pharmaceuticals has higher earnings, but lower revenue than Navidea Biopharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Ampio Pharmaceuticals has a beta of 7.65, suggesting that its stock price is 665% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPE vs. The Competition

Export
MetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$6K$889.47M$6.25B$22.95B
Dividend YieldN/A4.84%2.73%4.03%
P/E Ratio0.001.7129.0428.58
Price / SalesN/A120.50476.6123.57
Price / CashN/A20.0727.6219.03
Price / Book0.007.609.674.68
Net Income-$8.63M-$4.80M$3.55B$1.07B
7 Day PerformanceN/A-0.05%1.70%0.89%
1 Month PerformanceN/A5.50%5.62%6.56%
1 Year PerformanceN/A30.96%34.41%31.66%

Ampio Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPE
Ampio Pharmaceuticals
N/A$0.01
flat		N/AN/A$6KN/AN/A20
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
VAXX
Vaxxinity
N/A$0.00
flat		N/AN/A$13KN/AN/A90
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/AN/A$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel